Tirofiban combined with heparin versus heparin alone in acute coronary syndrome patients undergoing emergency PCI: A retrospective study of no-reflow and myocardial perfusion
Year: 2026
Type: article
Study design: Observational Study
Abstract: The no-reflow phenomenon is an important complication of emergency percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). We examined the association between adjunctive tirofiban and in-hospital angiographic and electrocardiographic reperfusion indicators. This single-center retrospective observational study included 186 ACS patients who underwent emergency PCI between January 2021 and December 2024. According to perioperative antithrombotic treatment, patients were divided into a tirofiban plus heparin group (n = 92) and a heparin-alone group (n = 94). Because treatment assignment was nonrandom and determined by the treating interventional cardiologist, the analysis was designed to estimate associations rather than causal treatment effects. For the no-reflow outcome, a parsimonious multivariable logistic regression model adjusted for clinically relevant measured confounders, including diabetes mellitus, symptom-to-balloon time > 6 hours, high thrombus burden, and pre-PCI thrombolysis in myocardial infarction (grade/flow) (TIMI) 0-1 flow. No-reflow was recorded in 8/92 (8.7%) versus 20/94 (21.3%) patients (P = .016). Final TIMI grade 3 flow occurred in 91.3% versus 79.8% (P = .028); myocardial blush grade 2-3 in 84.8% versus 68.1% (P = .008); TIMI myocardial perfusion grade 2-3 in 82.6% versus 66.0% (P = .010); and ST-segment resolution > 70% in 65.2% versus 47.9% (P = .017). The originally reported adjusted odds ratio for no-reflow associated with tirofiban was 0.36 (95% confidence interval 0.14-0.90; P = .029). Bleeding Academic Research Consortium major bleeding occurred in 3/92 (3.3%) versus 2/94 (2.1%; P = .679); Bleeding Academic Research Consortium minor bleeding in 6/92 (6.5%) versus 5/94 (5.3%; P = .733). These small event counts do not establish comparable safety. In ACS patients undergoing emergency PCI, tirofiban plus heparin was associated with a lower incidence of intraoperative no-reflow and with improved surrogate markers of epicardial and myocardial reperfusion compared with heparin alone. These findings are hypothesis-generating and require confirmation in prospective studies with standardized treatment protocols and longer-term clinical follow-up.
Source: Medicine
Authors: Zhanqun Pan, Yan Yang, Zhao Luo
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: tirofiban, heparin, acute coronary syndrome, emergency percutaneous coronary intervention, no-reflow phenomenon, myocardial reperfusion, TIMI myocardial perfusion, bleeding complications, antiplatelet therapy, glycoprotein IIb/IIIa inhibitors, bleeding risk stratification, bleeding risk score 3
Open Access status: gold
Estimated APC paid: $1,950
OpenAlex ID: W7226005405
